Here is the design of a clinical trial:

Official Title: Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus Bacteremia

Included conditions:
- Staphylococcal Bacteraemia

Study Armgroups:
- {'label': 'Arm 1 (Dalbavancin)', 'type': 'EXPERIMENTAL', 'description': 'Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) \\<30 and not on dialysis. N=100', 'interventionNames': ['Drug: Dalbavancin']}
- {'label': 'Arm 2 (Standard of Care)', 'type': 'ACTIVE_COMPARATOR', 'description': 'For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100', 'interventionNames': ['Drug: Cefazolin', 'Drug: Daptomycin', 'Drug: Nafcillin', 'Drug: Oxacillin', 'Drug: Vancomycin']}

Interventions:
- {'type': 'DRUG', 'name': 'Cefazolin', 'description': 'Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)', 'armGroupLabels': ['Arm 2 (Standard of Care)']}
- {'type': 'DRUG', 'name': 'Dalbavancin', 'description': 'A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species', 'armGroupLabels': ['Arm 1 (Dalbavancin)']}
- {'type': 'DRUG', 'name': 'Daptomycin', 'description': 'Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks', 'armGroupLabels': ['Arm 2 (Standard of Care)']}
- {'type': 'DRUG', 'name': 'Nafcillin', 'description': 'Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)', 'armGroupLabels': ['Arm 2 (Standard of Care)']}
- {'type': 'DRUG', 'name': 'Oxacillin', 'description': 'Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks', 'armGroupLabels': ['Arm 2 (Standard of Care)']}
- {'type': 'DRUG', 'name': 'Vancomycin', 'description': 'Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)', 'armGroupLabels': ['Arm 2 (Standard of Care)']}

Primary Outcomes:
- {'measure': 'Desirability of Outcome Ranking (DOOR)', 'description': 'DOOR is a composite endpoint assessed by: (1) Clinical Failure: Lack of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment; (2) Infectious Complications such as: Endocarditis, New evidence of metastatic foci of infection, relapse - isolation of baseline S. aureus pathogen from a blood culture drawn after randomization, readmission for subsequent care of indication under study, need for additional unplanned source control procedures, or change in antibiotic therapy due to inadequate clinical response; (3) Serious Adverse Events (SAEs); (4) Adverse Events (AEs) Leading to Study Drug Discontinuation; and (5) Death. Clinical failure and infectious complications were assessed by a blinded adjudication committee. Participants missing clinical failure were treated as having clinical failure for calculation of DOOR.', 'timeFrame': 'Day 70'}

Please estimate the sample size based on the assumption: 
90% power, 2.5% significance level, 12% missing/dropout rate
Sample size {14}
        The study is powered for a superiority comparison of the primary objective, a comparison of DOOR. The probability of a subject from the dalbavancin arm having a superior DOOR ranking relative to a subject from the standard of care arm (Wilcoxon-Mann-Whitney U statistic) will be used as a summary measure for the comparison. Assuming a 65% probability the dalbavancin arm will have a better DOOR than the standard of care arm, the number of participants (equally sized groups) needed to reach 90% power at 2.5% significance level for one-sided Wilcoxon-Mann-Whitney U test is 78 participants per arm (nQuery AdvisorÂ®, version 8.0). To account for potential loss to follow-up or dropout with approximately 12% missingness, we plan to recruit 100 per arm, i.e., 200 in total. A sample size of 200 results in at least 95.6% power.